Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Sanz G, Stauder R, Holm MS, Mittelman M, Mądry K, Malcovati L, Tatic A, Almeida AM, Germing U, Savic A, Gredelj Šimec N, Culligan D, Itzykson R, Guerci-Bresler A, Slama B, van de Loosdrecht A, van Marrewijk C, Droste J, Blijlevens N, van Kraaij M, Bowen D, de Witte T, Smith A; EUMDS Registry Participants.

Haematologica. 2019 Jul 5. pii: haematol.2018.212332. doi: 10.3324/haematol.2018.212332. [Epub ahead of print]

2.

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Šimec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2019 Jun 6. pii: haematol.2018.212217. doi: 10.3324/haematol.2018.212217. [Epub ahead of print]

3.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellström-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, Mądry K, Germing U, Almeida AM, Tatic A, Savic A, Šimec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Luño E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T.

Leuk Res. 2018 Apr;67:21-26. doi: 10.1016/j.leukres.2018.01.022. Epub 2018 Jan 31.

4.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee.

Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.

5.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.

de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenková D, Vallespí T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellström-Lindberg E, Čermák J, Stauder R, Tatic A, Holm MS, Malcovati L, Mądry K, Droste J, Blijlevens N, de Witte T, Germing U.

Ann Hematol. 2017 Jul;96(7):1105-1112. doi: 10.1007/s00277-017-3009-7. Epub 2017 May 20.

6.

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

J Intern Med. 2017 Mar;281(3):284-299. doi: 10.1111/joim.12579. Epub 2016 Dec 7.

7.

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

de Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MC, Porter JB, Mattijssen VE, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW.

Haematologica. 2016 Jan;101(1):38-45. doi: 10.3324/haematol.2015.133983. Epub 2015 Sep 18.

8.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T.

Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.

PMID:
25907546
9.

[Non-transferrin-bound iron: a promising biomarker in iron overload disorders].

Maas RP, Voets PJ, de Swart L, Swinkels DW.

Ned Tijdschr Geneeskd. 2013;157(49):A6258. Review. Dutch.

PMID:
24299624

Supplemental Content

Loading ...
Support Center